{
    "nctId": "NCT00084669",
    "briefTitle": "Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer",
    "officialTitle": "Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hot Flashes, Sleep Disorders",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 119,
    "primaryOutcomeMeasure": "Sleep improvement by biologic data and actigraphy data at the end of study treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At increased risk of developing breast cancer, meeting 1 of the following criteria:\n\n  * Diagnosis of 1 of the following:\n\n    * Ductal carcinoma in situ\n    * Invasive breast cancer\n    * Lobular carcinoma in situ\n    * Atypical ductal or lobular hyperplasia\n    * Lobular carcinoma\n  * Candidate for breast cancer risk reduction for any of the following:\n\n    * Predisposing mutation in a breast cancer susceptibility gene\n    * Prior chest radiotherapy for Hodgkin's disease\n    * Gail model score \\> 1.67% over 5 years\n* Experiencing daytime and nocturnal hot flushes at least 14 times per week within the past 2 weeks\n* Experiencing sleep disturbance, characterized by the presence of all of the following for \u2265 1 month:\n\n  * \u2265 3 awakenings per night occurring \u2265 3 nights per week\n  * Insomnia impedes daytime function\n  * Hot flushes are the primary cause of insomnia (determined at baseline visit)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 to 65\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* At least 6 months\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN\n\nRenal\n\n* Creatinine \u2264 1.5 times ULN\n\nCardiovascular\n\n* No clinically significant cardiac disease\n* No uncontrolled hypertension within the past 3 months, defined as the following:\n\n  * Diastolic blood pressure \\> 95 mm Hg on \\> 1 occasion\n  * Systolic blood pressure \\> 160 mm Hg on \\> 1 occasion\n\nPulmonary\n\n* No clinically significant respiratory disease\n\nPsychiatric\n\n* Beck depression inventory score \u2264 15\n* No active panic or depressive disorder within the past month\n* No lifetime history of bipolar or psychotic disorder\n* No active substance-use disorders, including alcohol and benzodiazepines, within the past year\n* No suicidal or homicidal ideation\n* No hypomania or mania\n\nOther\n\n* No prior adverse reaction to venlafaxine or zolpidem\n* None of the following sleep disorders within the past 6 months:\n\n  * Sleep apnea\n  * Narcolepsy\n  * Periodic limb movement disturbance\n* No abuse or misuse of study medication\n* No daytime sedation that interferes with ability to function\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception during and for 1 month after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* More than 3 months since prior chemotherapy\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* More than 1 month since prior regular use (\\> 25% of the time) of oral, transdermal, or injection preparations of androgens, estrogens, or progestins\n\n  * Vaginal suppositories and creams allowed\n* No concurrent regular use of oral, transdermal, or injection preparations of androgens, estrogens, or progestins\n\nRadiotherapy\n\n* See Disease Characteristics\n* More than 3 months since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* More than 1 month since prior regular use (\\> 25% of the time) of any of the following:\n\n  * Hypnotic agents (e.g., benzodiazepines, zolpidem, zaleplon, trazodone, or diphenhydramine)\n  * Clonidine\n* More than 1 month since prior antidepressants or other medications that are known to influence mood \\> 25% of the time (no serotonin-reuptake inhibitors \\[SRI\\] stratum only)\n* Concurrent SRI required provided they were initiated \u2265 1 month ago at or above the minimum dose, including any of the following (concurrent SRI stratum only):\n\n  * Fluoxetine\n  * Paroxetine\n  * Paroxetine CR\n  * Sertraline\n  * Citalopram\n  * S-citalopram\n  * Venlafaxine\n  * Fluvoxamine\n* No concurrent warfarin\n* No concurrent hypnotic agents, clonidine, or antidepressants, or other medications known to influence sleep, or mood",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}